A combined case of macroprolactinoma, growth hormone excess and graves' disease

Medical Journal of Malaysia

Volumn 60, Issue 2, 2005, Pages 232-236

  Hussein, Zanariah ^a   Tress, B ^b   Colman, P G ^b  

^a PUTRAJAYA HOSPITAL   (Malaysia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

Graves' disease; Growth hormone; Hyperprolactinaemia; Prolactinoma; Testosterone; Thyroid autoantibodies

Indexed keywords

CABERGOLINE; ANTITHYROID AGENT; BIOLOGICAL MARKER; DOPAMINE RECEPTOR STIMULATING AGENT; GROWTH HORMONE; PROLACTIN; THYROID HORMONE;

ADULT; ANAMNESIS; ARTICLE; AUTOIMMUNE DISEASE; CASE REPORT; DOSE RESPONSE; FOLLOW UP; GALACTORRHEA; GRAVES DISEASE; HUMAN; HYPERTHYROIDISM; HYPOGONADISM; LABORATORY TEST; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PROLACTINOMA; SYMPTOMATOLOGY; BLOOD; HYPOPHYSIS TUMOR; SECRETION;

ADULT; ANTITHYROID AGENTS; BIOLOGICAL MARKERS; DOPAMINE AGONISTS; FOLLOW-UP STUDIES; GRAVES DISEASE; GROWTH HORMONE; HUMANS; MALE; PITUITARY NEOPLASMS; PROLACTIN; PROLACTINOMA; THYROID HORMONES;

EID: 24944456799     PISSN: 03005283     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (5)

1. Reber PM. Prolactin and immunomodulation. Am J Med. 1993; 95; 637-43.
2. Ferrari C, Boghen M, Paracchi A, Rampini P, Raiteri F, Benco R, et al. Thyroid autoimmunity in hyperprolactinemic disorders. Acta Endocrinologica 1983; 104: 35-41.
3. Keogh MA, Wittert GA. Effect of cabergoline on thyroid function in hyperprolactinemia. Clin Endocrinol 2002; 57: 699.
4. Iranmanesh A, Lizarralde G, Johnson ML, Veldhuis JD. Nature of altered GH secretion in hyperthyroidism. J Clin Endocrinol Metab. 1991; 72: 108-15.
5. Shimatsu A, Murabe H, Sasaki S. Hattori N, Tanoh T, Imura H. Secretory dynamics of growth hormone in an acromegalic patient associated with Grave's disease. J Clin Endocrinol Metab. 1990; 71: 1059-63.